Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03846895
Other study ID # 303/16-04-2018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 12, 2018
Est. completion date February 15, 2022

Study information

Verified date September 2022
Source National and Kapodistrian University of Athens
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the clinical efficacy and symptom relief of vaginal fractional CO2 laser treatment in post-menopausal women with Overactive Bladder syndrome(OAB). Post-menopausal women with OAB syndrome who receive β3 adrenergic receptors (mirabegron 50mg) treatment, will be randomized in two groups. Half participants will receive active CO2 laser therapy, while the other half will receive placebo CO2 laser therapy.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 15, 2022
Est. primary completion date September 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Postmenopausal women (= 12 months of amenorrhea or FSH = 40 after hysterectomy with bilateral oophorectomy) who receive ß3 adrenergic receptors (mirabegron 50 mg) treatment for OAB - Overactive bladder syndrome (OAB) - = 3 months symptoms of urgency, with or without urinary incontinence, and = 8 micturitions / 24h - At least 3 episodes of urgent urination (3rd-4th grade) as recorded in the patient perception intensity of urgency scale (PPiUS) during a 3 day urination calendar , with or without urinary incontinence. Exclusion Criteria: - Participants with: - Pelvic Organ Prolapse (POP) > stage II of the pelvic organ prolapse quantitation system (POP-Q) - Post void residual volume > 200 ml (measured by ultrasound) - Use of moisturizers or lubricants the last month - Use of vaginal estrogen in the last 6 months - Use of drugs for urinary incontinence - Use of psychotropic drugs - Symptomatic urinary tract infection - Active genital infection - Kidney or liver disease - Abnormal cardiac conduction, rate or rythm disorders - Diabetic neuropathy - Myasthenia gravis - History of malignant disease - Previous radio-chemo therapy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Microablative Fractional CO2 laser
3 therapies intravaginally administered will be applied at monthly intervals

Locations

Country Name City State
Greece Urogynecological Unit of Alexandra Hospital Athens

Sponsors (1)

Lead Sponsor Collaborator
National and Kapodistrian University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overactive Bladder questionaire (OAB-q) It consists of an 8 item symptom bother scale section and a 25 item health related quality of life scale section (HRQL). Scores of each domain of the 2 sections range from 0 to 100. Higher scores indicate higher impact of overactive bladder symptoms. 24 months
Primary 3 days voiding diary Assesses bladder function (frequency of micturition, urgency and urinary incontinence) 24 months
Secondary King's Health Questionnaire (KHQ) It has 3 sections: 1) general health and overall health related to urinary symptoms with 2 questions, 2) incontinence impact, role limitations, physical limitations, social limitations, personal limitations, emotions, sleep and energy, and severity coping measures with 19 questions and 3) bother or impact of urinary symptoms with 11 questions. Scores of each domain of the 2 sections range from 0 to 100. Scores of the third section range from 0 to 3. Higher scores indicate higher impact of urinary incontinence. 24 months
Secondary Patients Global Impression of Improvement (PGI-I) It is a single question with 7 possible answers. Patients will chose the answer that applies at their impression of improvement after the laser therapy 24 months
Secondary Urogenital Distress Inventory questionaire (UDI-6) It is a 6 item questionaire evaluating symptom distress of urinary incontinence and its impact on daily life. Scores range from 0 to 100. Higher scores indicate higher impact of urinary incontinence. 24 months
Secondary Pelvic Floor Impact Questionnaire-short form 7 (PFIQ-7) It is a 7 item questionaire evaluating how much bladder symptoms affect their activities, relationships, and feelings. 24 months
See also
  Status Clinical Trial Phase
Completed NCT00507169 - SVT-40776 in Patients Suffering From Overactive Bladder Syndrome Phase 2
Completed NCT02216214 - Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Phase 4
Completed NCT02294396 - Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Phase 4
Completed NCT01936870 - Drug Use Investigation for Toviaz
Completed NCT03903094 - A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Terminated NCT04451382 - PTNS vs Botox of Refractory OAB
Terminated NCT04641975 - A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) Phase 3
Completed NCT00366002 - Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Phase 4
Completed NCT02138747 - A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Phase 4
Completed NCT03602508 - Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Completed NCT03572231 - A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
Completed NCT05211193 - Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
Completed NCT04562090 - A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder Phase 4
Completed NCT00282932 - Detrol LA In Men With Overactive Bladder. Phase 4
Completed NCT01639794 - Vesitirim™ in Men Postmarketing Observational Study N/A
Completed NCT00742833 - A Phase II Study of KUC-7483 in Patients With Overactive Bladder Phase 2
Withdrawn NCT01317810 - A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication N/A